Boston Scientific Corporation $BSX Shares Bought by Groupe la Francaise

Key Points

• Groupe la Francaise increased its stake in Boston Scientific Corporation by 13.1%, owning 335,082 shares worth approximately $33.6 million following a recent acquisition of 38,701 shares.
• Insider transactions reveal significant selling activity, with EVP Arthur C. Butcher selling 17,313 shares and Director Edward J. Ludwig selling 4,000 shares, impacting their ownership percentages.
• Boston Scientific reported $0.75 EPS for the last quarter, exceeding expectations of $0.72, and achieved a robust revenue of $5.06 billion, a year-over-year increase of 22.8%.

Groupe la Francaise boosted its holdings in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 13.1% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 335,082 shares of the medical equipment provider's stock after buying an additional 38,701 shares during the quarter. Groupe la Francaise's holdings in Boston Scientific were worth $33,591,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the business. HM Payson & Co. raised its position in Boston Scientific by 1.4% during the 1st quarter. HM Payson & Co. now owns 6,875 shares of the medical equipment provider's stock worth $694,000 after buying an additional 98 shares during the last quarter. Baldwin Investment Management LLC raised its position in Boston Scientific by 1.2% during the 4th quarter. Baldwin Investment Management LLC now owns 8,740 shares of the medical equipment provider's stock worth $781,000 after buying an additional 102 shares during the last quarter. Park Square Financial Group LLC raised its position in Boston Scientific by 5.2% during the 1st quarter. Park Square Financial Group LLC now owns 2,066 shares of the medical equipment provider's stock worth $208,000 after buying an additional 103 shares during the last quarter. HHM Wealth Advisors LLC raised its position in Boston Scientific by 13.2% during the 1st quarter. HHM Wealth Advisors LLC now owns 881 shares of the medical equipment provider's stock worth $89,000 after buying an additional 103 shares during the last quarter. Finally, Forum Financial Management LP raised its position in Boston Scientific by 0.8% during the 1st quarter. Forum Financial Management LP now owns 13,448 shares of the medical equipment provider's stock worth $1,357,000 after buying an additional 112 shares during the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Boston Scientific

In other news, EVP Arthur C. Butcher sold 17,313 shares of the company's stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the completion of the sale, the executive vice president owned 23,600 shares of the company's stock, valued at $2,469,268. This represents a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Edward J. Ludwig sold 4,000 shares of the company's stock in a transaction on Friday, July 25th. The stock was sold at an average price of $106.03, for a total transaction of $424,120.00. Following the sale, the director directly owned 18,479 shares of the company's stock, valued at $1,959,328.37. The trade was a 17.79% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 345,029 shares of company stock valued at $35,976,603. 0.50% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on BSX shares. Wall Street Zen raised shares of Boston Scientific from a "hold" rating to a "buy" rating in a report on Tuesday, April 29th. Morgan Stanley lifted their target price on shares of Boston Scientific from $120.00 to $125.00 and gave the company an "overweight" rating in a report on Friday, May 16th. Leerink Partnrs raised shares of Boston Scientific to a "strong-buy" rating in a report on Monday, June 16th. Oppenheimer lifted their target price on shares of Boston Scientific from $110.00 to $118.00 and gave the company a "market perform" rating in a report on Thursday, July 24th. Finally, Citigroup reaffirmed a "buy" rating and set a $125.00 target price (up from $119.00) on shares of Boston Scientific in a report on Thursday, May 22nd. Three analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, Boston Scientific has an average rating of "Buy" and a consensus price target of $117.50.

Boston Scientific Price Performance

Shares of NYSE BSX opened at $105.9950 on Friday. The firm has a market cap of $157.06 billion, a PE ratio of 63.09, a PEG ratio of 2.53 and a beta of 0.66. The firm has a fifty day moving average of $104.10 and a 200 day moving average of $102.16. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. Boston Scientific Corporation has a one year low of $78.53 and a one year high of $108.94.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. The company had revenue of $5.06 billion during the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The firm's revenue was up 22.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, research analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.